Latest Aspenbio Pharma (APPY) Headlines
Venaxis to Discuss Top-Line Results from Pivotal Study of APPY1 Test
PR Newswire - Wed Mar 12, 4:15PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will host a conference call to discuss top-line results from its pivotal study of the APPY1 Test tomorrow, Thursday, March 13, 2014, at 8:30 a.m. ET. The conference call will be hosted by Steve Lundy, Chief Executive Officer.
REMINDER/Media Advisory: Parliamentary Secretary Block to Highlight Government Investments in Clean Energy
Marketwire Canada - Wed Feb 26, 5:00AM CST
Parliamentary Secretary Kelly Block, on behalf of the Honourable Joe Oliver, Canada's Minister of Natural Resources, will deliver remarks about the Government of Canada's investments in clean energy during an event to mark Let's Talk Energy Week at the Museum of Science and Technology.
NBA Legend and Business Leader Magic Johnson Shares Empowerment Message as Part of Black History Month
PR Newswire - Tue Feb 11, 11:08AM CST
Earvin "Magic" Johnson is speaking at several events on Allstate's Northbrook, Ill campus discussing the role of education in his life, including the importance of staying in school, and the story of his transformation from athlete to business leader.
Analysis of the LED Lighting Market in the GCC
PR Newswire - Tue Feb 04, 7:42AM CST
Reportbuyer.com just published a new market research report:
Investors look to Lighten Up on Shares of AspenBio Pharma, Shares Down 11.6% (APPY)
Comtex SmarTrend(R) - Mon Jan 27, 11:41AM CST
AspenBio Pharma (NASDAQ:APPY) is one of today's worst performing low-priced stocks, down 11.6% to $2.20 on 1.6x average daily volume. AspenBio Pharma has traded 835,000 shares thus far today, vs. average volume of 538,000 shares per day. The stock has underperformed the Dow (-11.6% to the Dow's -0.4%) and underperformed the S&P 500 (-11.6% to the S&P's -0.8%) during today's trading.
Venaxis Inc concludes milestone patient enrollment in pivotal clinical trial of APPY1 Test
M2 - Mon Jan 27, 5:59AM CST
In vitro diagnostic company Inc (Nasdaq:APPY) revealed on Friday the completion of patient enrollment in the US under its pivotal clinical study of the APPY1 Test.
Hot Stock: AspenBio Pharma, Shares Drop 6.3% (APPY)
Comtex SmarTrend(R) - Fri Jan 24, 10:11AM CST
AspenBio Pharma (NASDAQ:APPY) is one of today's worst performing low-priced stocks, down 6.3% to $2.53 on 1.6x average daily volume. Thus far today, AspenBio Pharma has traded 861,000 shares, vs. average volume of 540,000 shares per day. The stock has underperformed the Dow (-6.3% to the Dow's -1.0%) and underperformed the S&P 500 (-6.3% to the S&P's -1.1%) during today's trading.
Venaxis Completes Patient Enrollment in Pivotal Clinical Trial of APPY1(TM) Test
PR Newswire - Fri Jan 24, 6:33AM CST
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced completion of patient enrollment in its pivotal clinical study of the APPY1 Test in the United States. Venaxis expects to announce top-line data following the required patient follow-up period and subsequent database lock and required analysis of the data. The study enrolled patients at approximately 27 hospital sites across the United States, and the pivotal data will be based on approximately 2,000 net evaluable patients.
Spinnaker Support Achieves Record Results and Market Traction in 2013
PR Newswire - Thu Jan 23, 6:00AM CST
Spinnaker Support, a global market leader for SAP, JD Edwards, and Siebel third-party maintenance, application/technical management services, and consulting, today announced a year of tremendous growth as a result of its record-breaking sales and market share gains.
Hot Stock: AspenBio Pharma, Shares Gain 6.0% (APPY)
Comtex SmarTrend(R) - Thu Jan 16, 10:43AM CST
AspenBio Pharma (NASDAQ:APPY) is one of today's best performing low-priced stocks, up 6.0% to $2.65 on 1.6x average daily volume. AspenBio Pharma has traded 715,000 shares thus far today, vs. average volume of 456,000 shares per day. The stock has outperformed the Dow (6.0% to the Dow's -0.5%) and outperformed the S&P 500 (6.0% to the S&P's -0.3%) during today's trading.
Social Media Marketing University Announces Its December 2013 Master Certification Program Graduates
PR Newswire - Wed Jan 15, 7:30AM CST
Social Media Marketing University (SMMU) announced today that 8 students received their Master Certification in December. Each student was required to take six core courses and two electives, and pass the program exam. Students have up to one year to complete the program.
Venaxis to Present at Biotech Showcase(TM) 2014
PR Newswire - Thu Jan 09, 8:09AM CST
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will present at the Biotech Showcase 2014 conference, to be held January 13-15, 2014, at The Parc 55 Wyndham Hotel in San Francisco, CA.
5 Stocks Under $10 Set to Soar
at The Street - Thu Dec 19, 1:48PM CST
These under-$10 stocks look ready to trade higher from current levels.
Investors look to Lighten Up on Shares of AspenBio Pharma, Shares Down 6.2% (APPY)
Comtex SmarTrend(R) - Mon Dec 09, 11:44AM CST
AspenBio Pharma (NASDAQ:APPY) is one of today's worst performing low-priced stocks, down 6.2% to $1.80 on 1.1x average daily volume. Thus far today, AspenBio Pharma has traded 392,000 shares, vs. average volume of 342,000 shares per day. The stock has underperformed the Dow (-6.2% to the Dow's 0.1%) and underperformed the S&P 500 (-6.2% to the S&P's 0.3%) during today's trading.
AspenBio Pharma Up 10.8%, Shares Break Through Resistance (APPY)
Comtex SmarTrend(R) - Mon Nov 25, 11:43AM CST
AspenBio Pharma (NASDAQ:APPY) is one of today's best performing low-priced stocks, up 10.8% to $1.84 on 1.2x average daily volume. AspenBio Pharma has traded 436,000 shares thus far today, vs. average volume of 360,000 shares per day. The stock has outperformed the Dow (10.8% to the Dow's 0.2%) and outperformed the S&P 500 (10.8% to the S&P's 0.1%) during today's trading.
Venaxis to Present at Piper Jaffray 25th Annual Healthcare Conference
PR Newswire - Thu Nov 21, 3:05PM CST
CASTLE ROCK, Colo., Nov. 21, 2013 /PRNewswire/-- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will present at the Piper Jaffray 25th Annual Healthcare Conference, to be held December 3-4, 2013, at The New York Palace Hotel in New York, NY.
Venaxis to Present at Canaccord Genuity Medical Technology & Diagnostics Forum
PR Newswire - Thu Nov 07, 3:05PM CST
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will present at the Canaccord Genuity Medical Technology & Diagnostics Forum, to be held Thursday November 14, 2013, at the Westin Grand Central in New York, NY.
Stock to Watch: AspenBio Pharma Down 9.4% (APPY)
Comtex SmarTrend(R) - Thu Nov 07, 12:48PM CST
AspenBio Pharma (NASDAQ:APPY) is one of today's worst performing low-priced stocks, down 9.4% to $1.64 on 1.1x average daily volume. AspenBio Pharma has traded 829,000 shares thus far today, vs. average volume of 731,000 shares per day. The stock has underperformed the Dow (-9.4% to the Dow's -0.5%) and underperformed the S&P 500 (-9.4% to the S&P's -0.7%) during today's trading.
Venaxis to Discuss Top-Line Results from Pivotal Study of APPY1 Test
PR Newswire - Wed Mar 12, 4:15PM CDT
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance for and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will host a conference call to discuss top-line results from its pivotal study of the APPY1 Test tomorrow, Thursday, March 13, 2014, at 8:30 a.m. ET. The conference call will be hosted by Steve Lundy, Chief Executive Officer.
REMINDER/Media Advisory: Parliamentary Secretary Block to Highlight Government Investments in Clean Energy
Marketwire Canada - Wed Feb 26, 5:00AM CST
Parliamentary Secretary Kelly Block, on behalf of the Honourable Joe Oliver, Canada's Minister of Natural Resources, will deliver remarks about the Government of Canada's investments in clean energy during an event to mark Let's Talk Energy Week at the Museum of Science and Technology.
NBA Legend and Business Leader Magic Johnson Shares Empowerment Message as Part of Black History Month
PR Newswire - Tue Feb 11, 11:08AM CST
Earvin "Magic" Johnson is speaking at several events on Allstate's Northbrook, Ill campus discussing the role of education in his life, including the importance of staying in school, and the story of his transformation from athlete to business leader.
Analysis of the LED Lighting Market in the GCC
PR Newswire - Tue Feb 04, 7:42AM CST
Reportbuyer.com just published a new market research report:
Investors look to Lighten Up on Shares of AspenBio Pharma, Shares Down 11.6% (APPY)
Comtex SmarTrend(R) - Mon Jan 27, 11:41AM CST
AspenBio Pharma (NASDAQ:APPY) is one of today's worst performing low-priced stocks, down 11.6% to $2.20 on 1.6x average daily volume. AspenBio Pharma has traded 835,000 shares thus far today, vs. average volume of 538,000 shares per day. The stock has underperformed the Dow (-11.6% to the Dow's -0.4%) and underperformed the S&P 500 (-11.6% to the S&P's -0.8%) during today's trading.
Venaxis Inc concludes milestone patient enrollment in pivotal clinical trial of APPY1 Test
M2 - Mon Jan 27, 5:59AM CST
In vitro diagnostic company Inc (Nasdaq:APPY) revealed on Friday the completion of patient enrollment in the US under its pivotal clinical study of the APPY1 Test.
Hot Stock: AspenBio Pharma, Shares Drop 6.3% (APPY)
Comtex SmarTrend(R) - Fri Jan 24, 10:11AM CST
AspenBio Pharma (NASDAQ:APPY) is one of today's worst performing low-priced stocks, down 6.3% to $2.53 on 1.6x average daily volume. Thus far today, AspenBio Pharma has traded 861,000 shares, vs. average volume of 540,000 shares per day. The stock has underperformed the Dow (-6.3% to the Dow's -1.0%) and underperformed the S&P 500 (-6.3% to the S&P's -1.1%) during today's trading.
Venaxis Completes Patient Enrollment in Pivotal Clinical Trial of APPY1(TM) Test
PR Newswire - Fri Jan 24, 6:33AM CST
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1 Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced completion of patient enrollment in its pivotal clinical study of the APPY1 Test in the United States. Venaxis expects to announce top-line data following the required patient follow-up period and subsequent database lock and required analysis of the data. The study enrolled patients at approximately 27 hospital sites across the United States, and the pivotal data will be based on approximately 2,000 net evaluable patients.
Spinnaker Support Achieves Record Results and Market Traction in 2013
PR Newswire - Thu Jan 23, 6:00AM CST
Spinnaker Support, a global market leader for SAP, JD Edwards, and Siebel third-party maintenance, application/technical management services, and consulting, today announced a year of tremendous growth as a result of its record-breaking sales and market share gains.
Hot Stock: AspenBio Pharma, Shares Gain 6.0% (APPY)
Comtex SmarTrend(R) - Thu Jan 16, 10:43AM CST
AspenBio Pharma (NASDAQ:APPY) is one of today's best performing low-priced stocks, up 6.0% to $2.65 on 1.6x average daily volume. AspenBio Pharma has traded 715,000 shares thus far today, vs. average volume of 456,000 shares per day. The stock has outperformed the Dow (6.0% to the Dow's -0.5%) and outperformed the S&P 500 (6.0% to the S&P's -0.3%) during today's trading.
Social Media Marketing University Announces Its December 2013 Master Certification Program Graduates
PR Newswire - Wed Jan 15, 7:30AM CST
Social Media Marketing University (SMMU) announced today that 8 students received their Master Certification in December. Each student was required to take six core courses and two electives, and pass the program exam. Students have up to one year to complete the program.
Venaxis to Present at Biotech Showcase(TM) 2014
PR Newswire - Thu Jan 09, 8:09AM CST
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will present at the Biotech Showcase 2014 conference, to be held January 13-15, 2014, at The Parc 55 Wyndham Hotel in San Francisco, CA.
5 Stocks Under $10 Set to Soar
at The Street - Thu Dec 19, 1:48PM CST
These under-$10 stocks look ready to trade higher from current levels.
Investors look to Lighten Up on Shares of AspenBio Pharma, Shares Down 6.2% (APPY)
Comtex SmarTrend(R) - Mon Dec 09, 11:44AM CST
AspenBio Pharma (NASDAQ:APPY) is one of today's worst performing low-priced stocks, down 6.2% to $1.80 on 1.1x average daily volume. Thus far today, AspenBio Pharma has traded 392,000 shares, vs. average volume of 342,000 shares per day. The stock has underperformed the Dow (-6.2% to the Dow's 0.1%) and underperformed the S&P 500 (-6.2% to the S&P's 0.3%) during today's trading.
AspenBio Pharma Up 10.8%, Shares Break Through Resistance (APPY)
Comtex SmarTrend(R) - Mon Nov 25, 11:43AM CST
AspenBio Pharma (NASDAQ:APPY) is one of today's best performing low-priced stocks, up 10.8% to $1.84 on 1.2x average daily volume. AspenBio Pharma has traded 436,000 shares thus far today, vs. average volume of 360,000 shares per day. The stock has outperformed the Dow (10.8% to the Dow's 0.2%) and outperformed the S&P 500 (10.8% to the S&P's 0.1%) during today's trading.
Venaxis to Present at Piper Jaffray 25th Annual Healthcare Conference
PR Newswire - Thu Nov 21, 3:05PM CST
CASTLE ROCK, Colo., Nov. 21, 2013 /PRNewswire/-- Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will present at the Piper Jaffray 25th Annual Healthcare Conference, to be held December 3-4, 2013, at The New York Palace Hotel in New York, NY.
Venaxis to Present at Canaccord Genuity Medical Technology & Diagnostics Forum
PR Newswire - Thu Nov 07, 3:05PM CST
Venaxis, Inc. (Nasdaq: APPY), an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1(TM) Test, a rapid, multiple biomarker-based assay for identifying patients that are at low risk for appendicitis, today announced it will present at the Canaccord Genuity Medical Technology & Diagnostics Forum, to be held Thursday November 14, 2013, at the Westin Grand Central in New York, NY.
Stock to Watch: AspenBio Pharma Down 9.4% (APPY)
Comtex SmarTrend(R) - Thu Nov 07, 12:48PM CST
AspenBio Pharma (NASDAQ:APPY) is one of today's worst performing low-priced stocks, down 9.4% to $1.64 on 1.1x average daily volume. AspenBio Pharma has traded 829,000 shares thus far today, vs. average volume of 731,000 shares per day. The stock has underperformed the Dow (-9.4% to the Dow's -0.5%) and underperformed the S&P 500 (-9.4% to the S&P's -0.7%) during today's trading.
